OM
WVE icon

Opaleye Management’s Wave Life Sciences WVE Stock Holding History

Opaleye Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-125,000
Closed -$2.33M – 39
2017
Q2 		$2.33M Buy
125,000
+46,700
+60% +$1.01M 0.97% 27
2017
Q1 		$2.15M Buy
+78,300
New +$2.19M 1.07% 29

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Opaleye Management's WVE Position: Q3 2017 in Review

Opaleye Management sold out of Wave Life Sciences (WVE) in Q3 2017, closing a stake of 125,000 shares — an estimated $2.33M sold.

Opaleye Management first reported a position in WVE in Q1 2017 and held it in 2 quarters. The position peaked at $2.33M in Q2 2017. 58 funds tracked by Wall St. Rank hold WVE as of Q3 2017.

  • Opaleye Management reported no remaining Wave Life Sciences position as of Q3 2017 after selling out during the quarter.
  • Opaleye Management sold 125,000 Wave Life Sciences shares in Q3 2017, an estimated $2.33M.
  • Opaleye Management first reported a position in Wave Life Sciences in Q1 2017 and held it in 2 quarters.
  • Opaleye Management's Wave Life Sciences position peaked at $2.33M in Q2 2017.
  • 58 funds tracked by Wall St. Rank held Wave Life Sciences as of Q3 2017.

Based on Opaleye Management's 13F filing for Q3 2017, filed 14 Nov 2017.